[go: up one dir, main page]

MX2019009720A - Metodos y composiciones para la transferencia de genes a traves de la vasculatura. - Google Patents

Metodos y composiciones para la transferencia de genes a traves de la vasculatura.

Info

Publication number
MX2019009720A
MX2019009720A MX2019009720A MX2019009720A MX2019009720A MX 2019009720 A MX2019009720 A MX 2019009720A MX 2019009720 A MX2019009720 A MX 2019009720A MX 2019009720 A MX2019009720 A MX 2019009720A MX 2019009720 A MX2019009720 A MX 2019009720A
Authority
MX
Mexico
Prior art keywords
methods
vasculature
genes
compositions
transfer
Prior art date
Application number
MX2019009720A
Other languages
English (en)
Inventor
Asokan Aravind
MURLIDHARAN Giridhar
ALBRIGHT Blake
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2019009720A publication Critical patent/MX2019009720A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripcion proporciona proteinas de la capside del AAV que comprenden una modificacion en la secuencia de aminoacidos y las capsides de virus y vectores de virus que comprenden la proteina de la capside del AAV modificada; la descripcion tambien proporciona metodos para administrar los vectores de virus y las capsides de virus de la descripción a una celula o a un sujeto in vivo.
MX2019009720A 2017-02-15 2018-02-15 Metodos y composiciones para la transferencia de genes a traves de la vasculatura. MX2019009720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459286P 2017-02-15 2017-02-15
PCT/US2018/018381 WO2018152333A1 (en) 2017-02-15 2018-02-15 Methods and compositions for gene transfer across the vasculature

Publications (1)

Publication Number Publication Date
MX2019009720A true MX2019009720A (es) 2019-10-07

Family

ID=63169716

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009720A MX2019009720A (es) 2017-02-15 2018-02-15 Metodos y composiciones para la transferencia de genes a traves de la vasculatura.

Country Status (13)

Country Link
US (2) US11905312B2 (es)
EP (1) EP3583220A4 (es)
JP (2) JP7291397B2 (es)
KR (1) KR20190117571A (es)
CN (2) CN118978574A (es)
AU (1) AU2018221738B2 (es)
BR (1) BR112019016769A2 (es)
CA (1) CA3052829A1 (es)
EA (1) EA038695B1 (es)
IL (2) IL312788A (es)
MX (1) MX2019009720A (es)
SG (1) SG11201907298WA (es)
WO (1) WO2018152333A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
EP3831842A1 (en) 2015-09-28 2021-06-09 The University of North Carolina at Chapel Hill Methods and compositions for antibody-evading virus vectors
KR20200042935A (ko) * 2017-08-25 2020-04-24 오비드 테라퓨틱스 인크. 재조합 아데노-관련된 벡터들
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
JP7438981B2 (ja) 2018-05-11 2024-02-27 マサチューセッツ アイ アンド イヤー インファーマリー アデノ随伴ウイルスの肝臓特異的向性
CN120843603A (zh) 2018-07-11 2025-10-28 布里格姆妇女医院 用于跨血脑屏障递送试剂的方法和组合物
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
CN121160803A (zh) 2018-09-28 2025-12-19 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
KR20210130158A (ko) * 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
IL285350B2 (en) 2019-02-04 2025-07-01 Spur Therapeutics Ltd Polynucleotides
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
TW202102526A (zh) * 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
TW202106708A (zh) * 2019-04-24 2021-02-16 美商銳進科斯生物股份有限公司 全人類轉譯後修飾之抗體治療劑
CA3151021A1 (en) * 2019-08-14 2021-02-18 University Of Florida Research Foundation, Incorporated Aav capsid variants for gene therapy
CN114667349A (zh) * 2019-09-09 2022-06-24 马萨诸塞眼科耳科诊所 用于调节腺相关病毒(aav)和aav受体(aavr)之间的相互作用以改变aav生物分布的方法和组合物
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
WO2021087007A1 (en) * 2019-10-28 2021-05-06 University Of Florida Research Foundation, Incorporated Gene therapy vectors
WO2021102234A1 (en) * 2019-11-22 2021-05-27 The Children's Hospital Of Philadelphia Adeno-associated viral vector variants
IL294608A (en) 2020-01-10 2022-09-01 Brigham & Womens Hospital Inc Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
MY209860A (en) 2020-02-13 2025-08-07 Tenaya Therapeutics Inc Gene therapy vectors for treating heart disease
WO2021163357A2 (en) 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
TW202142554A (zh) * 2020-02-25 2021-11-16 澳洲兒童醫學研究所 腺相關病毒蛋白殼多肽及載體
US20230151389A1 (en) * 2020-05-05 2023-05-18 Duke University Cross-species compatible adeno-associated virus compositions and methods of use thereof
BR112023003145A2 (pt) 2020-08-19 2023-05-09 Sarepta Therapeutics Inc Vetores de vírus adenoassociado para tratamento da síndrome de rett
JP2023545384A (ja) * 2020-10-07 2023-10-30 リジェネックスバイオ インコーポレイテッド 中枢神経系または筋肉送達のための組換えアデノ随伴ウイルス
WO2022076750A2 (en) * 2020-10-07 2022-04-14 Regenxbio Inc. Recombinant adeno-associated viruses for cns or muscle delivery
WO2022150634A2 (en) * 2021-01-08 2022-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav
US20240082351A1 (en) * 2021-01-13 2024-03-14 Duke University Compositions for and methods of improving fluid flux in the brain
CA3224488A1 (en) 2021-07-08 2023-01-12 Tenaya Therapeutics, Inc. Optimized expression cassettes for gene therapy
US20250281639A1 (en) * 2021-07-14 2025-09-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating chronic pain and for retrograde transduction of neurons
CN113563430B (zh) * 2021-07-30 2022-05-31 上海信致医药科技有限公司 用于治疗眼部疾病的基因递送系统及其应用
CN113480615B (zh) * 2021-07-30 2022-05-31 上海信致医药科技有限公司 高视网膜亲和性的新型腺相关病毒衣壳蛋白及其应用
AR126839A1 (es) * 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
PE20241995A1 (es) * 2021-08-20 2024-09-27 Biocad Joint Stock Co Metodo para obtener una capside de virus adenoasociado modificada
WO2023023781A1 (en) * 2021-08-25 2023-03-02 Children's Medical Research Institute Modified aav capsid polypeptides and vectors
US20240352077A1 (en) * 2021-08-25 2024-10-24 Children's Medical Research Institute Modified aav capsids and vectors
US20250179518A1 (en) * 2021-10-07 2025-06-05 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
CN114516901B (zh) * 2022-03-11 2023-01-17 上海勉亦生物科技有限公司 一种神经系统高亲和性的aav载体及其应用
WO2023201277A1 (en) * 2022-04-14 2023-10-19 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
TW202421787A (zh) 2022-09-06 2024-06-01 美商特納亞治療股份有限公司 保護心臟之心臟病療法
KR102855674B1 (ko) * 2022-10-06 2025-09-08 주식회사 글루진테라퓨틱스 폐 기관지 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
WO2024215653A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
WO2025015388A1 (en) * 2023-07-20 2025-01-23 Children's Medical Research Institute Modified cardiotropic aav capsid polypeptides and vectors
KR102868933B1 (ko) * 2023-11-08 2025-10-14 주식회사 글루진테라퓨틱스 성상세포 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터
WO2025121957A1 (ko) * 2023-12-06 2025-06-12 주식회사 글루진테라퓨틱스 뇌 성상교세포 특이적 유전자 전달이 가능한 아데노부속바이러스 변이체와 이의 응용
WO2025147741A1 (en) * 2024-01-11 2025-07-17 Children's Medical Research Institute Aav capsids and vectors for transduction of cells
CN119405806A (zh) * 2024-10-25 2025-02-11 南通大学 小肌营养蛋白域含2抑制剂在制备促进神经生长药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135468B1 (en) * 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19933288A1 (de) * 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
EP1496944B1 (en) * 2002-05-01 2008-08-20 University of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
ES2634118T3 (es) * 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
EP2782596A4 (en) * 2011-11-22 2015-07-29 Philadelphia Children Hospital VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENIC ADMINISTRATION
EP3738974A1 (en) * 2012-09-28 2020-11-18 The University of North Carolina at Chapel Hill Aav vectors targeted to oligodendrocytes
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US20180216133A1 (en) * 2015-07-17 2018-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells

Also Published As

Publication number Publication date
IL268534B2 (en) 2024-10-01
US20190367562A1 (en) 2019-12-05
AU2018221738A1 (en) 2019-08-22
EA038695B1 (ru) 2021-10-06
IL268534A (en) 2019-09-26
KR20190117571A (ko) 2019-10-16
JP2023052541A (ja) 2023-04-11
JP7291397B2 (ja) 2023-06-15
CN110520536B (zh) 2024-07-09
BR112019016769A2 (pt) 2020-05-26
US11905312B2 (en) 2024-02-20
WO2018152333A9 (en) 2019-01-24
JP2020505936A (ja) 2020-02-27
SG11201907298WA (en) 2019-09-27
CN110520536A (zh) 2019-11-29
EP3583220A1 (en) 2019-12-25
EP3583220A4 (en) 2021-07-07
JP7574508B2 (ja) 2024-10-29
EA201991911A1 (ru) 2020-02-20
CA3052829A1 (en) 2018-08-23
US20240209031A1 (en) 2024-06-27
CN118978574A (zh) 2024-11-19
WO2018152333A1 (en) 2018-08-23
IL312788A (en) 2024-07-01
AU2018221738B2 (en) 2024-06-27
IL268534B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
MX2019009720A (es) Metodos y composiciones para la transferencia de genes a traves de la vasculatura.
AR118465A1 (es) Vectores de virus adenoasociados recombinantes
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
BR112019002904A2 (pt) métodos e composições para transferência gênica direcionada
MX2020010465A (es) Vectores de virus para direccionamiento a tejidos oftalmicos.
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
MX2020010464A (es) Vectores de virus que evitan anticuerpos.
MX2022015079A (es) Variantes de hsd17b13 y usos de las mismas.
CL2018003196A1 (es) Cápsides variantes de virus adenoasociados y métodos de uso de estas.
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
CL2020001360A1 (es) Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis.
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
PE20211419A1 (es) Vectores virales recombinantes y acidos nucleicos para producirlos
CL2019000392A1 (es) Métodos para detectar aav.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
MX2019002938A (es) Mutaciones estebilizantes de trimeros de proteinas de la envoltura del vih.
ECSP17059343A (es) ARNi VARIANTE
HRP20210057T4 (hr) Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX373809B (es) Virus de la viruela porcina recombinante y vacunas.
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas